Craig Hallum Lowers AngioDynamics (ANGO) to Hold

Craig Hallum lowered shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a report published on Friday morning, MarketBeat Ratings reports.

Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of AngioDynamics from a hold rating to a buy rating and set a $19.00 price target on the stock in a research report on Tuesday, October 3rd. TheStreet lowered shares of AngioDynamics from a b- rating to a c rating in a research report on Tuesday, January 2nd. Canaccord Genuity restated a hold rating and issued a $17.00 price target on shares of AngioDynamics in a research report on Sunday, October 8th. Finally, KeyCorp restated a hold rating on shares of AngioDynamics in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $18.40.

AngioDynamics (ANGO) traded up $0.40 during trading hours on Friday, reaching $16.11. 540,900 shares of the company’s stock were exchanged, compared to its average volume of 457,600. The firm has a market capitalization of $591.97, a price-to-earnings ratio of -76.71, a PEG ratio of 1.57 and a beta of 1.04. AngioDynamics has a 52-week low of $14.80 and a 52-week high of $18.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.16. The firm had revenue of $86.70 million for the quarter, compared to analyst estimates of $88.15 million. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 earnings per share. analysts expect that AngioDynamics will post 0.68 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of AngioDynamics by 14.4% during the second quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock worth $31,416,000 after purchasing an additional 243,825 shares in the last quarter. Broadfin Capital LLC raised its stake in shares of AngioDynamics by 14.9% during the second quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock worth $27,286,000 after buying an additional 217,800 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of AngioDynamics by 49.4% during the third quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock worth $24,607,000 after buying an additional 476,327 shares during the last quarter. Northern Trust Corp raised its stake in shares of AngioDynamics by 14.9% during the second quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock worth $19,500,000 after buying an additional 155,951 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of AngioDynamics by 0.9% during the third quarter. Wells Fargo & Company MN now owns 1,025,233 shares of the medical instruments supplier’s stock worth $17,521,000 after buying an additional 9,639 shares during the last quarter. Institutional investors own 95.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/08/craig-hallum-lowers-angiodynamics-ango-to-hold.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

What are top analysts saying about AngioDynamics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit